Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health Care Trends (03/2007): The Case for Pay-for-Performance

Executive Summary

The pay-for-performance (P4P) model, which allows hospitals and physicians to be compensated with higher payer reimbursement for providing documented quality care, is becoming a standard practice with a growing number of private insurers, and the federal government wants to use a P4P system for Medicare.

You may also be interested in...

Improvements in Preventive Care Lacking

The push to improve healthcare quality in the U.S. has been a consistent goal, imbedded in the industry for years. However, over the last decade this movement rose to a higher level of necessity, and a number of programs have been generated from within the industry as well as government agencies -- but, has significant progress been made?

Employers Push EHRs into Wider Use

The goal of developing a nationwide system of electronic healthcare records (EHRs) for most all Americans is moving at a slower pace than some would like. But now, a group of large and influential employers has entered the picture with a plan that seems poised to change the speed and leadership of the endeavor.

Supplemental Filings: Califf Discusses Revolving Door; Poll Examines Public Trust In FDA Approvals

Commissioner expresses concern about agency lawyers leaving and then representing US FDA’s opponents in court. Also, as lawsuits about abortion pill continue, Kaiser Family Foundation finds the public trusts FDA more than the judiciary on determining products’ safety and effectiveness.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts